From Clinical Trials to Commercialization: The Pharma/Healthcare Global Supply Chain | Clinical Trial & Cold Chain Logistics
In this special episode of QuickConversations we’re joined by a guest speaker from our parent company, Kuehne+Nagel: Robert Coyle, Senior Vice President of Pharma & Healthcare Strategy. He joins QuickSTAT’s Scott Ohanesian, Senior Vice President...
The Pharma/Healthcare global supply chain is, needless to say, a complex and extensive one. It’s also a time-critical one, with careful planning, coordination and execution that’s simply non-negotiable. The road from clinical trials to final delivery of drugs into the marketplace must be carefully followed—with a complex journey that includes scientific labs, manufacturing sites, distribution centers, and ultimately, patients.
This special episode of QuickConversations features a guest speaker from our parent company, Kuehne+Nagel: Robert Coyle, Senior Vice President of Pharma & Healthcare Strategy. He joins QuickSTAT’s Scott Ohanesian, Senior Vice President Commercial Operations, Clinical Trial Logistics, for an in-depth conversation about the pharma/healthcare global supply chain. Host Chris Riback leads this informative discussion on the full product lifecycle that centers around:
This special episode of QuickConversations features a guest speaker from our parent company, Kuehne+Nagel: Robert Coyle, Senior Vice President of Pharma & Healthcare Strategy. He joins QuickSTAT’s Scott Ohanesian, Senior Vice President Commercial Operations, Clinical Trial Logistics, for an in-depth conversation about the pharma/healthcare global supply chain. Host Chris Riback leads this informative discussion on the full product lifecycle that centers around:
- The strategic components of this vital lifeline
- The significant planning and strategy required
- How all of the players in the pharma/healthcare supply chain can best communicate and coordinate
- And how to be prepared when unexpected events—including one of the magnitude of COVID-19—dictate an immediate shift in plans